Literature DB >> 2482060

Increased levels of IgG subclasses specific for Pseudomonas aeruginosa exoenzyme and polysaccharide antigens in chronically infected patients with cystic fibrosis.

A Albus1, M Saalmann, H Tesch, S S Pedersen, G Döring.   

Abstract

IgG subclass levels to Pseudomonas aeruginosa alginate, alkaline proteinase, elastase and exotoxin A in sera of healthy adults, non-infected and infected cystic fibrosis patients were investigated by enzyme linked immunosorbent assay. Whereas healthy adults and non-infected cystic fibrosis patients revealed mostly negative IgG subclass levels to the four antigens, infected cystic fibrosis patients had significantly elevated IgG1, IgG2, IgG3 and IgG4 levels to both the protein antigens as well as the polysaccharide antigen. The study does not support previous findings of an impaired natural IgG2 response to polysaccharide antigen. The study does not support previous findings of an impaired natural IgG2 response to polysaccharide in chronically infected cystic fibrosis patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2482060     DOI: 10.1111/j.1699-0463.1989.tb00531.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.428


  3 in total

1.  A second operator is involved in Pseudomonas aeruginosa elastase (lasB) activation.

Authors:  R M Anderson; C A Zimprich; L Rust
Journal:  J Bacteriol       Date:  1999-10       Impact factor: 3.490

2.  Determination of IgG subclass antibodies to Pseudomonas aeruginosa outer membrane proteins in cystic fibrosis lung infection using immunoblotting and enzyme-linked immunosorbent assay.

Authors:  T Pressler; G Kronborg; G H Shand; B Mansa; N Høiby
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

3.  Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis.

Authors:  R G Cowan; G B Winnie
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.